Common
- Symbol
- STAA
- Exchange
- NASDAQ
- Classification
- OTHER
- Status
- Current
Current Report · Items 2.02, 7.01, 9.01 · 8-K
STAANASDAQEQUITYCurrent
Item 2.02 Results of Operations and Financial Condition. On August 12, 2026, STAAR Surgical Company (the “Company”) published a press release reporting its financial results for the quarter ended July 3, 2026, a copy of which is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.
Press release in this filing
STAAR Surgical Reports Second Quarter 2026 Results Net Sales of $93.5 million, up 111% Y/Y →STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for over 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer® Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICLs are clinically proven to deliver safe long-term vision correction without removing corneal tissue or the eye's natural crystalline lens. Its EVO ICL™ product line provides visual freedom through a quick, minimally invasive procedure.
STAAR SURGICAL CO · 8-K · Filed 2026-08-12
EX-99.1 2 staa-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 STAAR Surgical Reports Second Quarter 2026 Results Net Sales of $93.5 million, up 111% Y/Y Net Income of $8.1 million, with GAAP EPS of $0.16 Adjusted EBITDA1 of $20.0 million, or $0.39 per diluted share Earnings Call and Webcast Today at 5:30 PM Eastern LAKE FOREST, CA, [August 12, 2026] --- STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the second quarter ended July 3, 2026. Second Quarter 2026 Financial Overview • Net sales of $93.5 million, up 111% Y/Y • Net sales excluding China of $41.2 million, up 6.0% Y/Y • China sales of $52.3 million up over 100%, 10% sequentially • APAC sales up 189% Y/Y, ex-China sales up 7% Y/Y • Americas up 12% Y/Y • EMEA down 1% Y/Y, ex-Middle East up 12% Y/Y • Gross margin at 74.5% vs. 74.0% a year ago • Net income of $8.1 million, or $0.16 per diluted share, compared to a net loss of $(16.8) million, or $(0.34) per diluted share a year ago • Adjusted EBITDA1 of $20.0 million, or $0.39 per diluted share, compared to Adjusted EBITDA1 loss …
Open exhibit ↗